Myeloid-derived Suppressor Cells in Autoimmune Diabetes: Their Antidiabetic Potential and MechanismWen-Chin Yang1-5*
- Corresponding Author:
- Dr. Wen-Chin Yang
Agricultural Biotechnology Research Center
Academia Sinica, No. 128, Academia Sinica Rd. Sec. 2
Nankang, Taipei 11529, Taiwan
Email: [email protected]
Received Date: April 01, 2013; Accepted Date: May 01, 2013; Published Date: May 06, 2013
Citation: Yang WC (2013) Myeloid-derived Suppressor Cells in Autoimmune Diabetes: Their Anti-diabetic Potential and Mechanism. J Diabetes Metab S12:004. doi:10.4172/2155-6156.S12-004
Copyright: © 2013 Yang WC. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Autoimmune diabetes is caused by a destruction of pancreatic β-cells by autoreactive immune response, leading to insulin insufficiency/deficiency and hyperglycemia and fatal complications. This disease afflicts up to 10 million people worldwide. There is no cure for autoimmune diabetes. Insulin injection is the only supportive medication, which always accompanies fatality. Apart from replacement therapy using insulin and/or β-cells, immune interventions hold the key to stopping this illness. Myeloid-derived suppressor cells have emerged as a new regulator in harnessing immune response. In this review, we first up-dated the advances on etiology, development and immune interventions of autoimmune diabetes. Next, we highlighted the origin, development, tolerogenic mechanisms of myeloid-derived suppressor cells with an emphasis of the signaling pathways in their development and action. Finally, we summarized and discussed the recent progress in exploring the potential and mechanism of myeloid-derived suppressor cells in autoimmune diabetes. A novel vista on MDSC-based immune intervention with AID development was also discussed.